Potential Treatment to Prevent Toxic Protein Clumping Enters Phase 1 Trial, Yumanity Announces

Potential Treatment to Prevent Toxic Protein Clumping Enters Phase 1 Trial, Yumanity Announces
Yumanity Therapeutics announced the start of a Phase 1 clinical study in healthy volunteers that will assess the safety and tolerability of YTX-7739, a potential disease-modifying therapy for Parkinson’s disease. Trial results are expected to be announced in the first quarter of 2020. YTX-7739 is designed to cross the blood-brain-barrier — a semipermeable membrane that protects the brain and spinal cord ... read more
Source: Parkinson’s News TodayPublished on 2019-10-10By Alice Melão